Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies

Table 1

Inhibitory concentration 50 (IC₅₀) of the major pharmaceutical compounds in clinical development for the treatment of thyroid cancer segregated with respect to the kinase activity required to inhibit different molecular targets (nmol/L).

Pharmaceutical compound	VEGFR1	VEGFR2	VEGFR3	RET	RET/PTC	PDGFRβ	BRAF	KIT	Others (IC50)
Sorafenib	26	90	20	47	50	57	25	68	—
Motesanib	2	3	6	59	—	84	—	8	—
Axitinib	0.1	0.2	0.29	1.2	—	2	—	1.7	—
Sunitinib	10	10	10	100	224	39	—	1–10	—
Vandetanib	—	40	110	130	100	—	—	—	EGFR (500)
Pazopanib	10	30	47	—	—	84	—	74	—
Lenvatinib (E7080)	22	4	5.2	35	—	39	—	—	FGFR1 (46)
Cabozantinib (XL-184)	—	0.035	—	4	—	—	—	—	C-MET (1.8)